infliximab (remicade) Report issue

Biologics mAb Orphan Drug FDA Approved FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet's disease. It is given by slow injection into a vein, typically at six- to eight-week intervals.   Wikipedia

More Chemistry

Drug Pricing (per unit)

United States

$17.3455 - $610.4100

Australia

$248.6465 - $257.0430
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

abp 710 | bay 103356 | bay-103356 | bay w 3356 | bay-w 3356 | bay-w-3356 | bms-224819 | ca2 | cdp 571 | cdp-571 | ct-p13 | humicade | inflectra | infliximab | infliximab-abda | infliximab-dyyb | infliximab-qbtx | remicade | remsima | teneliximab

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue